RCM
KERX

RA Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

RA Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,000,000
Closed -$10.1M – 43
2013
Q3 		$10.1M Hold
1,000,000
– – 1.05% 24
2013
Q2 		$7.47M Buy
+1,000,000
New +$7.81M 0.99% 21

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

RA Capital Management's KERX Position: Q3 2015 in Review

RA Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 59,200 shares — an estimated $591K sold.

RA Capital Management first reported a position in KERX in Q2 2013 and held it in 6 quarters. The position peaked at $42.3M in Q2 2013. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

  • RA Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • RA Capital Management sold 59,200 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $591K.
  • RA Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 6 quarters.
  • RA Capital Management's Keryx Biopharmaceuticals Inc position peaked at $42.3M in Q2 2013.
  • 138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on RA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.